Author

A. Hage

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Research Focus:cell signaling & trafficking· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

R. Rajsbaum· 5 shared V. D. Menachery· 3 shared A. N. Freiberg· 2 shared P.-Y. Shi· 2 shared X. Xie· 2 shared A. Bukreyev· 1 shared A. M. Vallero-Jimenez· 1 shared A. Odle· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

R. Rajsbaum

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication

M. Gonzalez-Orozco, H.-c. Tseng, A. Hage, H. Xia, P. Behera, K. Afreen, Y. Penaflor-Tellez, M. I. Giraldo, M. Huante, L. Puebla-Clark, S. van Tol, A. Odle, M. Crown, N. Teruel, T. R. Shelite, , R. Rajsbaum

This study identifies TRIM7 as an E3-ubiquitin ligase that ubiquitinates SARS-CoV-2 M protein to inhibit apoptosis and viral replication.

bioRxiv · Jun 17, 2024Microbiology

A novel mechanism of regulation of the transcription factor GLI3 by toll-like receptor signaling

S. J. Matissek, W. Han, A. Hage, M. Karbalivand, R. Rajsbaum, S. F. Elsawa

This paper identifies TLR4-TRIF-IRF3 signaling as a novel pathway regulating GLI3 expression and its role in inflammatory cytokine secretion.

bioRxiv · Jan 1, 2021 · PreprintImmunology

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.

K. G. Lokugamage, A. Hage, M. Devries, A. M. Vallero-Jimenez, C. Schindewolf, M. Dittmann, R. Rajsbaum, V. D. Menachery

This study compares the sensitivity of SARS-CoV-2 and SARS-CoV to type I interferon, finding SARS-CoV-2 is more susceptible to IFN-I treatment.

Journal of Virology · Nov 9, 2020Peer-reviewedMicrobiology

Topoisomerase III-beta is required for efficient replication of positive-sense RNA viruses

K. R. Prasanth, M. Hirano, W. S. Fagg, E. McAnarney, S. Chan, X. Xie, A. Hage, C. Pietzsch, A. Bukreyev, R. Rajsbaum, P.-Y. Shi, M. Bedford, S. Bradrick, V. D. Menachery, M. A. Garcia-Blanco

The paper identifies TOP3B as essential for replication of positive-sense RNA viruses, including SARS-CoV-2, suggesting it as a potential antiviral target.

bioRxiv · Mar 24, 2020Microbiology

Peptidoglycan associated cyclic lipopeptide disrupts viral infectivity

B. A. Johnson, A. Hage, B. Kalveram, M. Mears, J. A. Plante, S. E. Rodriguez, Z. Ding, X. Luo, D. Bente, S. S. Bradrick, A. N. Freiberg, V. Popov, R. Rajsbaum, S. Rossi, W. K. Russell, V. D. Menachery

The paper identifies surfactin, a cyclic lipopeptide from bacterial peptidoglycan, as a broad-spectrum virucidal compound that disrupts enveloped virus infectivity.

bioRxiv · May 13, 2019Microbiology